BridgeBio Pharma, Inc. (NASDAQ:BBIO) CFO Sells $2,467,720.00 in Stock

BridgeBio Pharma, Inc. (NASDAQ:BBIO) CFO Brian C. Stephenson sold 68,000 shares of BridgeBio Pharma stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $36.29, for a total value of $2,467,720.00. Following the completion of the sale, the chief financial officer now owns 93,758 shares in the company, valued at approximately $3,402,477.82. The trade was a 42.04 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

BridgeBio Pharma Price Performance

NASDAQ:BBIO traded down $0.49 during midday trading on Thursday, reaching $35.97. The stock had a trading volume of 2,154,592 shares, compared to its average volume of 2,899,899. BridgeBio Pharma, Inc. has a 1-year low of $21.62 and a 1-year high of $41.04. The stock has a market capitalization of $6.80 billion, a P/E ratio of -14.93 and a beta of 1.05. The firm’s fifty day simple moving average is $29.64 and its 200-day simple moving average is $27.10.

Institutional Investors Weigh In On BridgeBio Pharma

Several hedge funds have recently modified their holdings of BBIO. Rhumbline Advisers increased its stake in BridgeBio Pharma by 2.3% in the fourth quarter. Rhumbline Advisers now owns 219,120 shares of the company’s stock valued at $6,013,000 after acquiring an additional 5,007 shares during the period. Legato Capital Management LLC acquired a new position in BridgeBio Pharma in the fourth quarter worth $210,000. Harvey Capital Management Inc. bought a new position in shares of BridgeBio Pharma in the fourth quarter worth about $354,000. China Universal Asset Management Co. Ltd. raised its position in BridgeBio Pharma by 10.8% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 40,073 shares of the company’s stock worth $1,100,000 after purchasing an additional 3,908 shares during the last quarter. Finally, Atomi Financial Group Inc. acquired a new stake in BridgeBio Pharma in the fourth quarter worth about $392,000. 99.85% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research analysts recently commented on BBIO shares. Leerink Partners reduced their price objective on BridgeBio Pharma from $47.00 to $46.00 and set an “outperform” rating for the company in a research note on Thursday, October 17th. Bank of America lifted their target price on BridgeBio Pharma from $42.00 to $45.00 and gave the company a “buy” rating in a research report on Monday, November 25th. Evercore ISI increased their price objective on shares of BridgeBio Pharma from $45.00 to $50.00 and gave the stock an “outperform” rating in a research report on Monday, December 23rd. Oppenheimer began coverage on BridgeBio Pharma in a research report on Thursday, October 3rd. They issued a “market perform” rating for the company. Finally, HC Wainwright reiterated a “buy” rating and issued a $49.00 target price on shares of BridgeBio Pharma in a report on Monday, December 16th. Two research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $48.08.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.